Funian Lu
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal and related cancers 2
- Gut microbiota and health 2
- Oncology 9
- PARP inhibition in cancer therapy 4
- Cancer Cells and Metastasis 2
- Co-authors
- Gang Chen (12 shared papers)Rourou Xiao (12 shared papers)Bin Yang (9 shared papers)Xianda Zhao (4 shared papers)Honglei Chen (4 shared papers)Lixin You (4 shared papers)Chen Zhao (4 shared papers)Ensong Guo (6 shared papers)
- Journals
- Aging (2 papers)Gynecologic Oncology (1 paper)International Immunology (1 paper)The Journal of Experimental Medicine (1 paper)Microbial Ecology (1 paper)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Funian Lu
20 papers receiving 434 citations
Peers
Comparison fields: 5 of 62
- Cancer Research 67
- Oncology 110
- Reproductive Medicine 29
- Immunology 65
- Molecular Biology 201
Countries citing papers authored by Funian Lu
This map shows the geographic impact of Funian Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Funian Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Funian Lu more than expected).
Fields of papers citing papers by Funian Lu
This network shows the impact of papers produced by Funian Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Funian Lu. The network helps show where Funian Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Funian Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 72 | |
| 2 | 2021 | 54 | |
| 3 | 2021 | 40 | |
| 4 | 2006 | 34 | |
| 5 | Dysregulation of JAM-A plays an important role in human tumor progression. | 2014 | 34 |
| 6 | 2016 | 27 | |
| 7 | 2017 | 24 | |
| 8 | 2022 | 20 | |
| 9 | 2021 | 20 | |
| 10 | 2018 | 19 | |
| 11 | 2021 | 18 | |
| 12 | 2022 | 16 | |
| 13 | 1999 | 14 | |
| 14 | mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers. | 2020 | 14 |
| 15 | 2024 | 11 | |
| 16 | 2021 | 7 | |
| 17 | 2023 | 5 | |
| 18 | 2023 | 4 | |
| 19 | 2021 | 3 | |
| 20 | 2025 | 1 |
About Funian Lu
Funian Lu is a scholar working on Molecular Biology, Oncology, Immunology, Cancer Research and Obstetrics and Gynecology, having authored 20 papers that have together received 437 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (4 papers), Ovarian cancer diagnosis and treatment (2 papers), Renal and related cancers (2 papers), interferon and immune responses (2 papers), Gut microbiota and health (2 papers), Cancer Cells and Metastasis (2 papers), Barrier Structure and Function Studies (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Cancer Research (67 citations), Oncology (110 citations), Reproductive Medicine (29 citations), Immunology (65 citations) and Molecular Biology (201 citations). Funian Lu has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Gang Chen, Rourou Xiao, Bin Yang, Xianda Zhao, Honglei Chen, Lixin You, Chen Zhao, Ensong Guo, Chaoyang Sun and Chen Liu. Their work appears in journals such as Aging, Gynecologic Oncology, International Immunology, The Journal of Experimental Medicine and Microbial Ecology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.